Studying How Live Tumor Biopsies Can Predict Response to Immunotherapy in Adults with Suspected or Confirmed Cancer

What this Trial Is About

Researchers are studying the response to immunotherapy in patients with suspected or confirmed cancer by collecting tumor specimens during routine biopsy or similar procedures. The study focuses on analyzing live tumor biopsies to understand the tumor microenvironment and its immune cells intact. This research aims to compare the ex vivo tumor response to immunotherapy with the real-world clinical outcomes, helping to inform future treatment development. Participants will provide tumor tissue samples obtained during their standard medical biopsy procedures. Additional biopsy samples may be collected if clinically appropriate. Alongside these specimens, clinical and genomic data from the patients standard care will be used to support the research. The study does not involve administering new treatments but observes responses through collected tissue and data. Participants will undergo biopsies as part of their normal care, with no extra treatment required for the study. Information collected includes tumor tissue, clinical data, and genomic data. The main outcome measured is the ability to predict clinical response to immune checkpoint inhibitors. The study duration is about 36 months from enrollment to the studys end, allowing long-term data collection and analysis.

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)